Tags

Type your tag names separated by a space and hit enter

Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Int J Pharm. 2018 Jul 10; 545(1-2):261-273.IJ

Abstract

Hepatocellular carcinoma (HCC) continues to be a leading cause of cancer related death in the world. Conventional chemotherapeutic agents such as cisplatin (CDDP) have an unsatisfactory efficacy on HCC due to the poor response, severe toxicity and drug resistance. Curcumin (CUR) could improve the chemosensitivity of HCC to chemotherapy drugs by regulating a variety of signaling pathways. Herein, we describe a combination strategy using co-loaded liposomes to effectively deliver and release CDDP and curcumin (CUR) to HCC for overcoming the unsatisfactory clinical outcome of CDDP monotherapy. In the study, CDDP and CUR co-loaded liposomes (CDDP/CUR-Lip) were prepared by a reverse microemulsion and film dispersion method and their average particle size 294.6 ± 14.8 nm with uniform size distribution. In vitro study showed that the nano sized CDDP/CUR-Lip could synchronously release both CDDP and CUR to achieve the synergistic effect against HCC cells based on the optimal ratio (1:8) of both drugs. Compared with free drug or encapsulated mono-drug therapy, CDDP/CUR-Lip demonstrated the higher anti-tumor activity in vitro against HepG2 cells with the IC50 of 0.62 μM. In addition, CDDP/CUR-Lip also increased intracellular ROS level during the HCC cells treatment. Furthermore, compared with single drug formulation, CDDP/CUR-Lip showed the elongated retention time (t1/2 = 2.38 h) and improved antitumor effect in both mouse hepatoma H22 and human HCC HepG2 xenograft models with reduced side effects. In conclusion, CDDP/CUR-Lip provide an attractive and potential strategy to attain synergistic effect of CDDP and CUR for the treatment of HCC.

Authors+Show Affiliations

Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: xiangma@hust.edu.cn.Pharmacy School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: youjiti@mails.tjmu.edu.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29730175

Citation

Cheng, Yao, et al. "Cisplatin and Curcumin Co-loaded Nano-liposomes for the Treatment of Hepatocellular Carcinoma." International Journal of Pharmaceutics, vol. 545, no. 1-2, 2018, pp. 261-273.
Cheng Y, Zhao P, Wu S, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int J Pharm. 2018;545(1-2):261-273.
Cheng, Y., Zhao, P., Wu, S., Yang, T., Chen, Y., Zhang, X., He, C., Zheng, C., Li, K., Ma, X., & Xiang, G. (2018). Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. International Journal of Pharmaceutics, 545(1-2), 261-273. https://doi.org/10.1016/j.ijpharm.2018.05.007
Cheng Y, et al. Cisplatin and Curcumin Co-loaded Nano-liposomes for the Treatment of Hepatocellular Carcinoma. Int J Pharm. 2018 Jul 10;545(1-2):261-273. PubMed PMID: 29730175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. AU - Cheng,Yao, AU - Zhao,Pengxuan, AU - Wu,Shuangping, AU - Yang,Tan, AU - Chen,Yan, AU - Zhang,Xiaojuan, AU - He,Chuanchuan, AU - Zheng,Chao, AU - Li,Kelin, AU - Ma,Xiang, AU - Xiang,Guangya, Y1 - 2018/05/03/ PY - 2017/12/14/received PY - 2018/04/24/revised PY - 2018/05/01/accepted PY - 2018/5/8/pubmed PY - 2018/10/16/medline PY - 2018/5/7/entrez KW - Cisplatin (CDDP) KW - Hepatocellular carcinoma KW - Liposome KW - Synergistic combination nanotherapy KW - curcumin (CUR) SP - 261 EP - 273 JF - International journal of pharmaceutics JO - Int J Pharm VL - 545 IS - 1-2 N2 - Hepatocellular carcinoma (HCC) continues to be a leading cause of cancer related death in the world. Conventional chemotherapeutic agents such as cisplatin (CDDP) have an unsatisfactory efficacy on HCC due to the poor response, severe toxicity and drug resistance. Curcumin (CUR) could improve the chemosensitivity of HCC to chemotherapy drugs by regulating a variety of signaling pathways. Herein, we describe a combination strategy using co-loaded liposomes to effectively deliver and release CDDP and curcumin (CUR) to HCC for overcoming the unsatisfactory clinical outcome of CDDP monotherapy. In the study, CDDP and CUR co-loaded liposomes (CDDP/CUR-Lip) were prepared by a reverse microemulsion and film dispersion method and their average particle size 294.6 ± 14.8 nm with uniform size distribution. In vitro study showed that the nano sized CDDP/CUR-Lip could synchronously release both CDDP and CUR to achieve the synergistic effect against HCC cells based on the optimal ratio (1:8) of both drugs. Compared with free drug or encapsulated mono-drug therapy, CDDP/CUR-Lip demonstrated the higher anti-tumor activity in vitro against HepG2 cells with the IC50 of 0.62 μM. In addition, CDDP/CUR-Lip also increased intracellular ROS level during the HCC cells treatment. Furthermore, compared with single drug formulation, CDDP/CUR-Lip showed the elongated retention time (t1/2 = 2.38 h) and improved antitumor effect in both mouse hepatoma H22 and human HCC HepG2 xenograft models with reduced side effects. In conclusion, CDDP/CUR-Lip provide an attractive and potential strategy to attain synergistic effect of CDDP and CUR for the treatment of HCC. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/29730175/Cisplatin_and_curcumin_co_loaded_nano_liposomes_for_the_treatment_of_hepatocellular_carcinoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(18)30299-0 DB - PRIME DP - Unbound Medicine ER -